TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28656510
Drug: Alprostadil hydration
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil hydration (10 μg/day for 3 days plus 20 ml normal saline)
Study: 28656510
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 ml normal saline for 3 days)
Study: 3532009
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg three times a day for 4 weeks)
Study: 26636489
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant patch
Study: 29715355
Drug: Insulin (n=454)
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin (n=454)
Study: 28049818
Drug: Short-chain galactooligosaccharide
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain galactooligosaccharide (GOS) treatment, designated 'RP-G28', administered over 36 days.
Study: 26022709
Drug: FLAM (flavopiridol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLAM (flavopiridol 50 mg/m(2) days 1‐3, cytarabine 667 mg/m(2)/day continuous infusion days 6‐8, and mitoxantrone 40 mg/m(2) day 9)
Study: 26022709
Drug: 7+3 (cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7+3 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐7 and daunorubicin 90 mg/m(2) days 1‐3)
Study: 26022709
Drug: 7+3+/-5+2 (cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7+3+/-5+2 (cytarabine 100 mg/m(2)/day continuous infusion days 1‐5 and daunorubicin 45 mg/m(2) days 1‐2)
Study: 21497022
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg followed by two boluses of 0.5 mg/kg at 5-min intervals and continuous infusion)
Study: 21497022
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride administered at equivalent volume, dose and rate to lidocaine)
Study: 12925034
Drug: Lepirudin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lepirudin (bolus 0.1 mg kg‐1, continuous infusion of 0.1 mg kg‐1 h‐1)
Study: 12162483
Drug: HPMC-containing solution
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC-containing solution
Study: 12162483
Drug: Multipurpose solutions
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multipurpose solutions without HPMC
Study: 9672932
Drug: Withholding oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding oral fluids for 4-6 hours postoperatively
Study: 9672932
Drug: Drinking oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drinking oral fluids postoperatively
Study: 9672932
Drug: Withholding oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding oral fluids in patients receiving opioids
Study: 7916445
Drug: Atropine and
Normalized name: atropine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine and chlordesmethyldiazepam (0.03 mg/kg)
Study: 7916445
Drug: Atropine and
Normalized name: atropine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine and diazepam (0.015 mg/kg)
Study: 2690395
Drug: 252Cf neutron
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 252Cf neutron component applied by means of intracavitary therapy at the beginning of the therapeutic cure
Study: 2690395
Drug: Conventional 226Ra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 226Ra therapy (control group)
Study: 21192304
Drug: Clonidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (200 or 400 mcg)
Study: 21192304
Drug: Triamcinolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (40 mg)
Study: 19523011
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Study: 19523011
Drug: 270 microg
Normalized name: Interferon alfa-2a (as peginterferon alfa-2a) 270 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 270 microg week(‐1) PEG‐IFN alpha‐2a (40KD) + ribavirin (1000/1200 mg day(‐1)) for 48 weeks
Study: 17577435
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment group (intravascular embolism followed by immediate CSF drainage)
Study: 17577435
Drug: Conventional expectant
Normalized name: docosahexaenoic acid Oral Capsule [Expecta]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional expectant treatment group
Study: 11432512
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with 0.2% glyceryl trinitrate ointment
Study: 20037779
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (FEC-P)
Study: 11030486
Drug: Mirtazapine (15‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15‐45 mg/day)
Study: 29734896
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg triamcinolone acetonide
Study: 29734896
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone acetonide
Study: 24597289
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of GnRH agonist with recombinant hCG (rhCG)
Study: 20431040
Drug: Cyclosporine monotherapy
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine monotherapy followed by azathioprine and prednisolone after 3 months
Study: 18378552
Drug: Mecamylamine (MECA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (MECA, 20 mg, oral)
Study: 10359889
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol xinafoate 42 microgram twice daily
Study: 11549982
Drug: Oral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast 20 mg twice daily
Study: 1749203
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg b.i.d.)
Study: 1709240
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg o.d.)
Study: 1709240
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and chlorthalidone (20 mg b.i.d. and 25 mg o.d.)
Study: 31178377
Drug: ROTAVAC® (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROTAVAC® (3 doses)
Study: 31178377
Drug: Rotarix® (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix® (2 doses)
Study: 23106838
Drug: Fissure sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fissure sealant with oral hygiene instructions
Study: 17764475
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min exercise starting immediately after dosing (EX0)
Study: 17620446
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min exercise starting 30 min after dosing (EX30)
Study: 16123473
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI)
Study: 12691686
Drug: Weekly provider-initiated
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly provider-initiated follow-up calls for 1 month post-education
Study: 3797487
Drug: Salt tablets
Normalized name: bile salts Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt tablets for 4 weeks
Study: 3797487
Drug: Salt tablets
Normalized name: bile salts Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt tablets for 6 weeks
Study: 21989635
Drug: Repetitive task
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repetitive task specific training (RTP) for 6 weeks, approximately 2.5 hours per day, split into two sessions, with epidural cortical stimulation co-administered
Study: 22835600
Drug: Omega-3 polyunsaturated
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 polyunsaturated fatty acids (PUFAs) administered at ≥2.7 g/day for a minimum duration of 3 months
Study: 17607078
Drug: Nutritional agents
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional agents such as active vitamin D3 and vitamin K2
Study: 12006898
Drug: Moclobemide (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (75, 150, 300, 600, or 900 mg/day)
Study: 10096263
Drug: Interleukin-10 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-10 (8 microg/kg subcutaneous injection)
Study: 10096263
Drug: Prednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (15 mg by mouth)
Study: 8641320
Drug: Idrapril calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrapril calcium (200 mg)
Study: 6928104
Drug: Induction regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction regimen (vincristine plus low-dose methotrexate and high-dose prednisone)
Study: 27967288
Drug: Kabat physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabat physical rehabilitation combined with steroid treatment
Study: 27967288
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment alone
Study: 26055847
Drug: Oral iron,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron, folic acid, and anthelminthics prescribed after the first ANC visit.
Study: 24634110
Drug: Lacosamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (200 mg twice daily)
Study: 15331966
Drug: Temporal lobectomy
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporal lobectomy for drug-resistant temporo-mesial epilepsy
Study: 2651493
Drug: Zolpidem 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5.0 mg and larger doses
Study: 2651493
Drug: Zolpidem 7.5
Normalized name: zolpidem 7.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 7.5 mg and higher doses
Study: 28573779
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of skincare (Normaderm®) with fixed combination of adapalene/benzoyl peroxide
Study: 28573779
Drug: Standard emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard emollient alone with fixed combination of adapalene/benzoyl peroxide
Study: 23356386
Drug: MBL-HCV1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBL-HCV1 (50 mg/kg, 11 infusions)
Study: 19746439
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonists (LTRAs) in addition to fexofenadine (FEX) for 16 weeks
Study: 15345796
Drug: t‐PA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA therapy
Study: 11774075
Drug: Intravenous ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ribavirin treatment
Study: 9015579
Drug: Yohimbine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (up to 30 mg/day)
Study: 8235862
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation over the lower lumbar paraspinal muscles for 30 minutes twice a day.
Study: 28643069
Drug: Laparoscopic HIPEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic HIPEC with Mitomycin C 30 mg and Cisplatin 200 mg in 3-7 L of infusate for 60 min, performed up to five times.
Study: 19942485
Drug: ALV003 pre-treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALV003 pre-treated gluten (16 g daily for 3 days)
Study: 19942485
Drug: Placebo pre-treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pre-treated gluten (16 g daily for 3 days)
Study: 17511533
Drug: Cognitive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment group (n=16)
Study: 17511533
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment group (n=26)
Study: 11953285
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (Group B)
Study: 10364647
Drug: Tacrine 30
Normalized name: tacrine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine 30 mg/day for 6 weeks, 60 mg/day for 6 weeks, 90 mg/day for 6 weeks, 120 mg/day for 12 weeks
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 6.4 g/kg
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 7.2 g/kg
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 8.0 g/kg
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 8.8 g/kg
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 9.6 g/kg
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 10.4 g/kg
Study: 31265113
Drug: Dietary lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lysine level of 8.6 g/kg
Study: 27400922
Drug: Case Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case Management (CM) intervention consisting of assistance in obtaining income entitlements, referral to primary or specialty medical care, access to mental health care or substance abuse treatment, and counseling on at-risk behaviors and health care utilization.
Study: 24326412
Drug: Internal medicine/endocrinology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine/endocrinology practice
Study: 15831772
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (inhaled corticosteroids, 2 mg)
Study: 15831772
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (oral corticosteroids, 50 mg)
Study: 11691516
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen, 0.625 mg/day for 8 weeks
Study: 3280614
Drug: Dilazep (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep (0.2 mg/kg body weight by IV infusion for ten minutes)
Study: 31720819
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or cilostazol treatment with best medical therapy
Study: 29318443
Drug: Push intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Push intervention components of mHealth interventions (e.g., notifications or text messages)
Study: 29165753
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 0.5 μg/kg remifentanil (Control group)
Study: 29165753
Drug: Atomization inhalation
Normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomization inhalation of 15 mg ambroxol hydrochloride and 0.5 mg budesonide suspension (Observation group)
Study: 25831405
Drug: H2N2 live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2N2 live attenuated influenza vaccine (LAIV)
Study: 22633044
Drug: Cerebral protection
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral protection device (CPD) used in treatment
Study: 16430773
Drug: Starting calcium
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting calcium supplements
Study: 15928285
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug treatment
Study: 1466432
Drug: Fentanyl/propofol anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl/propofol anaesthesia (propofol infusion 6 mg.kg‐1.h‐1, reduced after 10 min)
Study: 6230648
Drug: Mezlocillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (2 g dose administered intravenously 1 hour before surgery)
Study: 30693399
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement + deproteinized bovine bone derived with collagen
Study: 30693399
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement without biomaterial
Study: 26500463
Drug: Zeolite supplementation
Normalized name: zeolite A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zeolite supplementation (1.85 g per day for 12 weeks)
Study: 21552183
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg mpHBV
Study: 21552183
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg mpHBV
Study: 21552183
Drug: Recombivax‐HB (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombivax‐HB (5 μg)
Study: 21552183
Drug: Engerix‐B (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix‐B (10 μg)
Study: 19843809
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg oral ondansetron the evening before surgery plus IV 8 mg ondansetron 15 min before subarachnoid anesthesia
Study: 10088569
Drug: rhGH, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH, 0.2 mg/kg per day intramuscularly (n = 10)
Study: 7502702
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g of calcium)
Study: 1953991
Drug: Alcohol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.75 g/kg body weight in 500 ml carbon dioxide‐free mineral water)
Study: 1953991
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (1,000 mg powdered, average 13.1 mg/kg body weight)
Study: 1953991
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and acetylsalicylic acid combination
Study: 24755382
Drug: Cronus (stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cronus (stent without polymer coating or drug elution)
Study: 22762317
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (≥800 IU daily)
Study: 22762317
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (unspecified dosage)
Study: 18784223
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg) at baseline
Study: 15916656
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel (0.5 mg intracervically)
Study: 15916656
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) (0.5 mg perivaginally)
Study: 15916656
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel (0.5 mg intracervically) in severely unfavorable cervix (Bishop score ≤3)
Study: 15916656
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) (0.5 mg perivaginally) in severely unfavorable cervix (Bishop score ≤3)
Study: 3525337
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg at night
Study: 12643609
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg in the morning
Study: 6778754
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (15 mg)
Study: 22113218
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (40 mg triamcinolone acetonide)
Study: 15708886
Drug: lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine 150 mg twice daily
Study: 12468950
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.), amoxycillin (1 g b.d.) for 7 days
Study: 12468950
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 5 days
Study: 12468950
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 7 days
Study: 12468950
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg o.d.), levofloxacin (500 mg o.d.) for 10 days
Study: 9844762
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CSA) at a dosage of 3 mg/kg/day
Study: 9844762
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at a dosage of 0.15 mg/kg/week
Study: 8029807
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day aspirin for seven days
Study: 8029807
Drug: 75 mg/day
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/day aspirin for seven days
Study: 8029807
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day aspirin for seven days
Study: 8029807
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg aspirin/day for one week